JP2002532382A5 - - Google Patents

Download PDF

Info

Publication number
JP2002532382A5
JP2002532382A5 JP2000568511A JP2000568511A JP2002532382A5 JP 2002532382 A5 JP2002532382 A5 JP 2002532382A5 JP 2000568511 A JP2000568511 A JP 2000568511A JP 2000568511 A JP2000568511 A JP 2000568511A JP 2002532382 A5 JP2002532382 A5 JP 2002532382A5
Authority
JP
Japan
Prior art keywords
composition
vegf
agonist
hypertension
native
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000568511A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002532382A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1999/020481 external-priority patent/WO2000013703A2/en
Publication of JP2002532382A publication Critical patent/JP2002532382A/ja
Publication of JP2002532382A5 publication Critical patent/JP2002532382A5/ja
Pending legal-status Critical Current

Links

JP2000568511A 1998-09-09 1999-09-09 高血圧を処置する方法およびそこでの使用のための組成物 Pending JP2002532382A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US9969498P 1998-09-09 1998-09-09
US12640699P 1999-03-26 1999-03-26
US12661599P 1999-03-27 1999-03-27
US60/099,694 1999-03-27
US60/126,406 1999-03-27
US60/126,615 1999-03-27
PCT/US1999/020481 WO2000013703A2 (en) 1998-09-09 1999-09-09 Methods of treating hypertension and compositions for use therein

Publications (2)

Publication Number Publication Date
JP2002532382A JP2002532382A (ja) 2002-10-02
JP2002532382A5 true JP2002532382A5 (cg-RX-API-DMAC7.html) 2006-10-26

Family

ID=27378887

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000568511A Pending JP2002532382A (ja) 1998-09-09 1999-09-09 高血圧を処置する方法およびそこでの使用のための組成物
JP2000568510A Pending JP2002524421A (ja) 1998-09-09 1999-09-09 微小血管障害の処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2000568510A Pending JP2002524421A (ja) 1998-09-09 1999-09-09 微小血管障害の処置

Country Status (13)

Country Link
US (3) US6352975B1 (cg-RX-API-DMAC7.html)
EP (2) EP1112083B1 (cg-RX-API-DMAC7.html)
JP (2) JP2002532382A (cg-RX-API-DMAC7.html)
AT (2) ATE253934T1 (cg-RX-API-DMAC7.html)
AU (2) AU5910599A (cg-RX-API-DMAC7.html)
BR (2) BR9913533A (cg-RX-API-DMAC7.html)
CA (2) CA2340728C (cg-RX-API-DMAC7.html)
DE (2) DE69912815T2 (cg-RX-API-DMAC7.html)
DK (2) DK1112083T3 (cg-RX-API-DMAC7.html)
ES (2) ES2211165T3 (cg-RX-API-DMAC7.html)
IL (2) IL141686A0 (cg-RX-API-DMAC7.html)
PT (2) PT1109571E (cg-RX-API-DMAC7.html)
WO (2) WO2000013702A2 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE253934T1 (de) * 1998-09-09 2003-11-15 Scios Inc Verwendung eines angiogenen faktors zur behandlung von mikrovaskulären angiopathien
US6783954B2 (en) * 1999-03-05 2004-08-31 Compugen Ltd. VEGF nucleic acid and amino acid sequences
JP2003513105A (ja) * 1999-11-02 2003-04-08 ジェネンテック・インコーポレーテッド eNOS活性の調節とその治療的使用
US7078382B1 (en) 1999-11-02 2006-07-18 Genentech, Inc. Modulation of eNOS activity and therapeutic uses thereof
US7129222B2 (en) * 2000-03-10 2006-10-31 Dynavax Technologies Corporation Immunomodulatory formulations and methods for use thereof
US20030129251A1 (en) 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
GB0008269D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
AU2002317333C1 (en) 2001-08-01 2009-06-25 University Of Bristol VEGF isoform
US7432301B2 (en) * 2001-08-20 2008-10-07 University Of Virginia Patent Foundation Use of S-nitrosothiol signaling to treat disordered control of breathing
US7981863B2 (en) * 2001-09-19 2011-07-19 Neuronova Ab Treatment of Parkinson's disease with PDGF
US7795213B2 (en) 2001-12-13 2010-09-14 Posco Methods of contacting β amyloid protein with VEGF
US20030171556A1 (en) * 2001-12-13 2003-09-11 Chi-Bom Chae Beta-amyloid binding factors and inhibitors thereof
US7335362B2 (en) 2002-07-19 2008-02-26 Beth Israel Deaconess Medical Center Methods of treating pre-eclampsia or eclampsia
JP2006068401A (ja) * 2004-09-03 2006-03-16 Kyushu Institute Of Technology 人工血管
JP2008537752A (ja) * 2005-04-12 2008-09-25 イントラディグム コーポレイション がんおよび他の新血管形成疾患を処置するためのRNAi治療用の組成物および方法
US7893244B2 (en) * 2005-04-12 2011-02-22 Intradigm Corporation Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
EP1964568B1 (en) * 2005-08-31 2014-03-26 National University Corporation Kagawa University Utilization of hypertension/hypercardia-preventing effect of d-allose
WO2010065671A2 (en) 2008-12-04 2010-06-10 Curna, Inc. Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf
GB0921525D0 (en) 2009-12-08 2010-01-27 Isis Innovation Product and method
WO2018183625A1 (en) 2017-03-30 2018-10-04 Wake Forest University Health Sciences Methods of treatment for kidney disease
CN113418940B (zh) * 2021-06-24 2023-03-14 电子科技大学 一种基于x射线示踪颗粒的检测方法及检测装置

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4456550A (en) 1982-11-22 1984-06-26 President And Fellows Of Harvard College Vascular permeability factor
US5240848A (en) 1988-11-21 1993-08-31 Monsanto Company Dna sequences encoding human vascular permeability factor having 189 amino acids
ES2103740T3 (es) 1989-03-24 1997-10-01 Univ California Factor de crecimiento celular endotelialico, su aislamiento y su expresion.
US5332671A (en) 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
US5219739A (en) 1989-07-27 1993-06-15 Scios Nova Inc. DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121
US5194596A (en) 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5240714A (en) * 1989-08-29 1993-08-31 Rof Jose M S Non-digoxin-like Na+, K+ -ATPase inhibitory factor
US5318957A (en) * 1992-09-02 1994-06-07 The United States Of America As Represented By The Department Of Health And Human Services Method of stimulating angiogenesis
AU729420B2 (en) * 1996-11-01 2001-02-01 Eurogene Limited Therapeutic use of growth factor, and delivery device, especially for the treatment of intimal hyperplasia
US6485942B1 (en) * 1997-02-14 2002-11-26 Genentech, Inc. Variants of vascular endothelial cell growth factor having altered pharmacological properties, and recombinant methods of production
ATE253934T1 (de) * 1998-09-09 2003-11-15 Scios Inc Verwendung eines angiogenen faktors zur behandlung von mikrovaskulären angiopathien

Similar Documents

Publication Publication Date Title
Timpl et al. [47] Laminin
Timpl et al. Characterization of protease-resistant fragments of laminin mediating attachment and spreading of rat hepatocytes.
Mollenhauer et al. Isolation and characterization of a collagen‐binding glycoprotein from chondrocyte membranes.
Avnur et al. The removal of extracellular fibronectin from areas of cell-substrate contact
Yamada Fibronectin and other structural proteins
TW214514B (cg-RX-API-DMAC7.html)
Power et al. Intra‐articular injection of rhFGF‐18 improves the healing in microfracture treated chondral defects in an ovine model
DE502004012225D1 (de) Generierung künstlicher bindungsproteine auf der grundlage von ubiquitin-proteinen
NO975435L (no) Modifiserte/kimeriske proteiner samt anvendelse derav
EA199900262A1 (ru) Ангиогенный фактор и способ его применения в лечении сердечно-сосудистого заболевания
JP2002517245A5 (cg-RX-API-DMAC7.html)
Nakatani et al. Expression of SPARC by activated hepatic stellate cells and its correlation with the stages of fibrogenesis in human chronic hepatitis
Center Chronic liver disease: current concepts of disease mechanisms
Cahill et al. Vascular atrial natriuretic factor receptor subtypes are not independently regulated by atrial peptides.
FR2816410B1 (fr) Necessaire de detection de la proteine esm-1 et procede de detection mettant en oeuvre ledit necessaire
Duzen et al. Identification of specific amino acid residues in the E. coli β processivity clamp involved in interactions with DNA polymerase III, UmuD and UmuD′
Nakane et al. Elafin, a secretory protein, is cross-linked into the cornified cell envelopes from the inside of psoriatic keratinocytes
Zippel et al. In vivo phosphorylation and dephosphorylation of the platelet-derived growth factor receptor studied by immunoblot analysis with phosphotyrosine antibodies
Khew et al. The specific recognition of a cell binding sequence derived from type I collagen by Hep3B and L929 cells
JP4233114B2 (ja) フォン・ブィレブランド因子の治療用フラグメント
WO1994014471A9 (en) Methods and compositions for inhibition of hepatic clearance of tissue-type plasminogen activator
Yurchenco et al. Laminin Self-Assembly: A Three-Arm Interaction Hypothesis for the Formation
Potter et al. Effects of differing purification methods on properties of keratose biomaterials
Shaeffer et al. Differential effects of ubiquitin aldehyde on ubiquitin and ATP-dependent protein degradation
Caswell et al. Location of ryanodine receptor binding site on skeletal muscle triadin